{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:33Z","timestamp":1787028513480,"version":"build-2736575974"},"reference-count":26,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Higher Education of the Russian Federation","award":["\u2116 075-15-2021-1061"],"award-info":[{"award-number":["\u2116 075-15-2021-1061"]}]},{"name":"Ministry of Science and Higher Education of the Russian Federation","award":["RF 193021X0029"],"award-info":[{"award-number":["RF 193021X0029"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice. The HRD status, including the BRCA status and genomic scar score (GSS), was analyzed in 452 ovarian cancer specimens. The successful rate of HRD testing was 86% (388\/452). The BRCA mutational rate was 29% (114\/388); 252 samples (65%) were classified as HRD-positive. Our data demonstrate the feasibility of internal HRD testing by the AmoyDx HRD Focus Panel for high-grade serous ovarian cancer (HGSOC), showing results similar to other methods. The HRD rate in the Russian population is very similar to those of other European populations, as is the BRCA mutation frequency. The most substantial contribution to HRD level diversity is testing criteria depending on intrahospital arrangements. The analysis shows that biallelic BRCA alterations had higher GSS compared with those with monoallelic inactivation, consistent with positive HRD status. The study indicates that grades 1\u20132 of the pathological response caused by chemotherapy affect HRD scores and suggests controlling for tumor purity of 40% or more as a critical factor for GSS measurement.<\/jats:p>","DOI":"10.3390\/ijms241310497","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T01:54:56Z","timestamp":1687485296000},"page":"10497","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?"],"prefix":"10.3390","volume":"24","author":[{"given":"Tatiana","family":"Kekeeva","sequence":"first","affiliation":[{"name":"Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Andreeva","sequence":"additional","affiliation":[{"name":"Department of Pathology, Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2177-6743","authenticated-orcid":false,"given":"Alexander","family":"Tanas","sequence":"additional","affiliation":[{"name":"Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-4581","authenticated-orcid":false,"given":"Alexey","family":"Kalinkin","sequence":"additional","affiliation":[{"name":"Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Khokhlova","sequence":"additional","affiliation":[{"name":"Oncological Department of Medical Treatment, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after V. I. Kulakov, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Tikhomirova","sequence":"additional","affiliation":[{"name":"N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Tyulyandina","sequence":"additional","affiliation":[{"name":"N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115478 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6267-8237","authenticated-orcid":false,"given":"Anatoly","family":"Popov","sequence":"additional","affiliation":[{"name":"National Medical Research Center of Surgery Named after A. Vishnevsky, Department of Antitumor Drug Therapy, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kuzmenko","sequence":"additional","affiliation":[{"name":"Department of Oncology, Radiology and Radiotherapy, Tyumen State Medical University, 625023 Tyumen, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Volkonsky","sequence":"additional","affiliation":[{"name":"Day Hospital No. 1, Moscow Municipal Oncological Hospital No. 62, 143423 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Chernorubashkina","sequence":"additional","affiliation":[{"name":"Department of Surgical Methods of Treatment No. 9, State Budgetary Healthcare Institution Regional Oncological Dispensary, 664035 Irkutsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Saevets","sequence":"additional","affiliation":[{"name":"Gynecological Oncology Department, Chelyabinsk Regional Clinical Centre for Oncology and Nuclear Medicine, 454087 Chelyabinsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Dmitriev","sequence":"additional","affiliation":[{"name":"Department of Theoretical Surgery, Belgorod National Research University, 308015 Belgorod, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nechushkina","sequence":"additional","affiliation":[{"name":"Department of Oncology, Diagnostic Radiology and Radiotherapy, Privolzhsky Research Medical University, 603005 Nizhniy Novgorod, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Vedrova","sequence":"additional","affiliation":[{"name":"Astrazeneca Pharmaceuticals LLC, 123112 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Andreev","sequence":"additional","affiliation":[{"name":"Astrazeneca Pharmaceuticals LLC, 123112 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Kutsev","sequence":"additional","affiliation":[{"name":"Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9283-902X","authenticated-orcid":false,"given":"Vladimir","family":"Strelnikov","sequence":"additional","affiliation":[{"name":"Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: A review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.36129\/jog.2022.34","article-title":"The role of preoperative frailty assessment in patients affected by gynecological cancer: A narrative review","volume":"34","author":"Baiocco","year":"2022","journal-title":"Ital. J. Gynaecol. Obstet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Petrucci, E., Pasquini, L., Bernabei, M., Saulle, E., Biffoni, M., Accarpio, F., Sibio, S., Giorgio, A.D., Donato, V.D., and Casorelli, A. (2012). A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035073"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41698-022-00276-6","article-title":"Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)","volume":"6","author":"Rempel","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"880643","DOI":"10.3389\/fonc.2022.880643","article-title":"Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors","volume":"12","author":"Mekonnen","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100144","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: Do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Leibowitz, B.D., Dougherty, B.V., Bell, J.S.K., Kapilivsky, J., Michuda, J., Sedgewick, A.J., Munson, W.A., Chandra, T.A., Dry, J.R., and Beaubier, N. (2022). Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09669-z"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/1471-0528.17324","article-title":"Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability","volume":"129","author":"Yuan","year":"2022","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Patel, A., Iyer, P., Matsuzaki, S., Matsuo, K., Sood, A., and Fleming, N. (2021). Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers, 13.","DOI":"10.3390\/cancers13040626"},{"key":"ref_16","unstructured":"Edge, S.B., Byrd, D.R., Compton, C.C., Fritz, A.G., Greene, F.L., and Trotti, I.I.I.A. (2010). AJCC. PART III: Digestive Systems. AJCC Cancer Staging Manual, Springer. [7th ed.]."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/modpathol.2013.134","article-title":"The estimation of tumor cell percentage for molecular testing by pathologists is not accurate","volume":"27","author":"Smits","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1158\/1538-7445.AM2018-1241","article-title":"Profile of BRCA1\/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study","volume":"78","author":"Tyulyandina","year":"2018","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-022-06782-2","article-title":"A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia","volume":"197","author":"Kechin","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zhong, Y., Liu, J., Li, X., Westin, S., Malpica, A., Lawson, B., Lee, S., Fellman, B.M., Coleman, R.L., and Sood, A.K. (2021). A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers, 13.","DOI":"10.3390\/cancers13040704"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1541-7786.MCR-17-0594","article-title":"Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma","volume":"16","author":"Arend","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-21-1104","article-title":"Patients with Biallelic BRCA1\/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types","volume":"27","author":"Wijngaart","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_23","first-page":"A1","article-title":"An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer","volume":"31","author":"Weichert","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Magliacane, G., Brunetto, E., Calzavara, S., Bergamini, A., Pipitone, G.B., Marra, G., Redegalli, M., Grassini, G., Rabaiotti, E., and Taccagni, G. (2022). Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!. Cancers, 15.","DOI":"10.3390\/cancers15010043"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.32074\/1591-951X-791","article-title":"In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: A feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay","volume":"114","author":"Fumagalli","year":"2022","journal-title":"Pathologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/35101031","article-title":"Two genetic hits (more or less) to cancer","volume":"1","author":"Knudson","year":"2001","journal-title":"Nat. Rev. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10497\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:58:46Z","timestamp":1760126326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":26,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310497"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310497","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]}}}